214390.KO Kyongbo Pharmaceutical Co Ltd
- Market cap
- KRW 122B
- P/E
- 24.3x
- P/B
- 0.82x
- ROE
- 3.3%
- Dividend yield
- 0.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 214390.KO undervalued?
Graham number214390.KO trades 5.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyongbo Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Kyongbo Pharmaceutical Co Ltd yet.
Kyongbo Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE.…
Full company profileKyongbo Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyongbo Pharmaceutical Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 187B | 192B | 201B | 192B | 215B | 171B | 196B | 216B | 239B | 264B | 283B |
| Gross Profit | 44.1B | 54.6B | 49.3B | 40.7B | 52.5B | 35.4B | 44.4B | 63.1B | 89.3B | 102B | 112B |
| Operating Income | 15.6B | 24.6B | 17.3B | 6.19B | 5.68B | -4.60B | 1.39B | 5.54B | 10.5B | 3.52B | 3.29B |
| EBITDA | 27.0B | 36.8B | 29.7B | 20.0B | 18.3B | 8.16B | 13.1B | 17.3B | 21.6B | 17.9B | 17.9B |
| Net Income | 12.7B | 18.0B | 13.1B | 5.29B | 9.40B | -7.50B | 611M | 2.97B | 4.64B | 182M | 4.89B |
| EPS | 531 | 751 | 549 | 221 | 393 | -314 | 26 | 124 | 194 | 7.63 | 204 |
| Balance Sheet | |||||||||||
| Total Assets | 204B | 205B | 222B | 238B | 253B | 237B | 241B | 266B | 284B | 320B | 368B |
| Total Liabilities | 74.3B | 63.4B | 72.6B | 88.7B | 97.2B | 91.3B | 96.8B | 122B | 138B | 174B | 221B |
| Shareholders' Equity | 129B | 142B | 149B | 149B | 156B | 146B | 144B | 144B | 146B | 146B | 147B |
| Cash & Short-term Investments | 4.58B | 6.40B | 4.99B | 6.77B | 21.0B | 4.29B | 7.22B | 4.48B | 4.13B | 7.23B | 6.92B |
| Total Debt | 41.1B | 28.8B | 42.6B | 56.4B | 63.3B | 56.6B | 64.5B | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 25.3B | 25.8B | -1.14B | 23.7B | 20.8B | 18.0B | 10.1B | 4.84B | 149M | 7.46B | 2.45B |
| Capital Expenditure | 19.7B | 7.40B | 8.19B | 23.2B | 12.4B | 18.3B | 13.2B | 10.9B | 13.2B | 41.6B | 64.9B |
| Free Cash Flow | 5.64B | 18.4B | -9.33B | 422M | 8.36B | -356M | -3.06B | -6.03B | -13.0B | -34.2B | -62.5B |
| Ratios | |||||||||||
| ROE | 9.8% | 12.7% | 8.8% | 3.5% | 6.0% | -5.1% | 0.4% | 2.1% | 3.2% | 0.1% | 3.3% |
| ROA | 6.2% | 8.8% | 5.9% | 2.2% | 3.7% | -3.2% | 0.3% | 1.1% | 1.6% | 0.1% | 1.3% |
| Net Profit Margin | 6.8% | 9.4% | 6.5% | 2.8% | 4.4% | -4.4% | 0.3% | 1.4% | 1.9% | 0.1% | 1.7% |
| Debt to Equity | 0.32x | 0.20x | 0.29x | 0.38x | 0.41x | 0.39x | 0.45x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kyongbo Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.98%
- Forward dividend
- 50.00 KRW
- Payout ratio
- 655.7%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.20B | 50 | 655.7% |
| 2024 | KRW 1.20B | 50 | 25.8% |
| 2023 | KRW 1.20B | 50 | 40.2% |
| 2022 | KRW 1.20B | 50 | 195.8% |
| 2021 | KRW 2.39B | 100 | - |
| 2020 | KRW 2.39B | 100 | 25.4% |
| 2019 | KRW 4.78B | 200 | 90.5% |
| 2018 | KRW 5.98B | 250 | 45.6% |
| 2017 | KRW 4.78B | 200 | 26.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Kyongbo Pharmaceutical Co Ltd
- Insiders 61.77%
- Institutions 0.08%
- Public & others 38.15%
- Shares outstanding 23.9M
- Free float 9.15M
Kyongbo Pharmaceutical Co Ltd company profile
- Company name
- Kyongbo Pharmaceutical Co Ltd
- Ticker
- 214390.KO
- ISIN
- KR7214390007
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 174, Sirok-ro, Asan-si, South Korea
- Phone
- 82 4 1420 0500
- Website
- kbpharma.co.kr
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research and development of Clopidogrel cardiovascular drug, Imatinlb anticancer drug, Donepezil anti-psychotic drug, Entecavir for anti-virus and infectious disease, and Esomeprazole. It also exports its products. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan-si, South Korea.
Kyongbo Pharmaceutical Co Ltd management
1- Tae-Young KimChief Executive Officer